Department of Bioengineering , Hanyang University , Seoul 04763 , Republic of Korea.
Center for Nanomedicine , Institute for Basic Science (IBS) , Seoul 03722 , Republic of Korea.
ACS Appl Mater Interfaces. 2019 May 1;11(17):15344-15353. doi: 10.1021/acsami.9b03242. Epub 2019 Apr 22.
Myelination by oligodendrocytes (OLs) is a key developmental milestone in terms of the functions of the central nervous system (CNS). Demyelination caused by defects in OLs is a hallmark of several CNS disorders. Although a potential therapeutic strategy involves treatment with the myelin-forming cells, there is no readily available source of these cells. OLs can be differentiated from pluripotent stem cells; however, there is a lack of efficient culture systems that generate functional OLs. Here, we demonstrate biomimetic approaches to promote OL differentiation from human-induced pluripotent stem cells (iPSCs) and to enhance the maturation and myelination capabilities of iPSC-derived OL (iPSC-OL). Functionalization of culture substrates using the brain extracellular matrix (BEM) derived from decellularized human brain tissue enhanced the differentiation of iPSCs into myelin-expressing OLs. Co-culture of iPSC-OL with induced neuronal (iN) cells on BEM substrates, which closely mimics the in vivo brain microenvironment for myelinated neurons, not only enhanced myelination of iPSC-OL but also improved electrophysiological function of iN cells. BEM-functionalized aligned electrospun nanofibrous scaffolds further promoted the maturation of iPSC-OLs, enhanced the production of myelin sheath-like structures by the iPSC-OL, and enhanced the neurogenesis of iN cells. Thus, the biomimetic strategy presented here can generate functional OLs from stem cells and facilitate myelination by providing brain-specific biochemical, biophysical, and structural signals. Our system comprising stem cells and brain tissue from human sources could help in the establishment of human demyelination disease models and the development of regenerative cell therapy for myelin disorders.
少突胶质细胞(OLs)的髓鞘形成是中枢神经系统(CNS)功能的一个关键发育里程碑。OL 缺陷导致的脱髓鞘是几种 CNS 疾病的标志。虽然一种潜在的治疗策略涉及用形成髓鞘的细胞进行治疗,但这些细胞没有现成的来源。OL 可以从多能干细胞中分化而来;然而,缺乏生成功能性 OL 的高效培养系统。在这里,我们展示了仿生方法来促进人诱导多能干细胞(iPSC)向 OL 的分化,并增强 iPSC 源性 OL(iPSC-OL)的成熟和髓鞘形成能力。使用源自去细胞化人脑组织的脑细胞外基质(BEM)对培养底物进行功能化,增强了 iPSC 向表达髓鞘的 OL 分化。在 BEM 底物上与诱导神经元(iN)细胞共培养,这种方法非常类似于体内有髓神经元的脑微环境,不仅增强了 iPSC-OL 的髓鞘形成,还改善了 iN 细胞的电生理功能。BEM 功能化的定向静电纺纳米纤维支架进一步促进了 iPSC-OL 的成熟,增强了 iPSC-OL 产生类似髓鞘鞘的结构,并增强了 iN 细胞的神经发生。因此,这里提出的仿生策略可以从干细胞中产生功能性 OL,并通过提供大脑特异性的生化、生物物理和结构信号来促进髓鞘形成。我们的系统包括来自人类来源的干细胞和脑组织,可以帮助建立人类脱髓鞘疾病模型,并开发用于髓鞘疾病的再生细胞治疗。